Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Shares Issued (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Shares Issued data on record, last reported at -$1.9 million in Q4 2025.

  • For Q4 2025, Shares Issued fell 162.32% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached $5.0 million, down 96.95%, while the annual FY2024 figure was $2.8 million, 125.1% up from the prior year.
  • Shares Issued reached -$1.9 million in Q4 2025 per ARQT's latest filing, down from $1.9 million in the prior quarter.
  • Across five years, Shares Issued topped out at $161.0 million in Q3 2024 and bottomed at -$14.1 million in Q2 2022.
  • Average Shares Issued over 5 years is $8.9 million, with a median of $100000.0 recorded in 2023.
  • Peak YoY movement for Shares Issued: tumbled 2083.66% in 2022, then soared 92647.7% in 2024.
  • A 5-year view of Shares Issued shows it stood at -$256000.0 in 2021, then soared by 106.25% to $16000.0 in 2022, then surged by 19275.0% to $3.1 million in 2023, then changed by 0.0% to $3.1 million in 2024, then plummeted by 162.32% to -$1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were -$1.9 million in Q4 2025, $1.9 million in Q3 2025, and -$395000.0 in Q2 2025.